Unknown

Dataset Information

0

The development of PARP inhibitors in ovarian cancer: from bench to bedside.

ABSTRACT: The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.

SUBMITTER: Drew Y 

PROVIDER: S-EPMC4816267 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The development of PARP inhibitors in ovarian cancer: from bench to bedside.

Drew Yvette Y  

British journal of cancer 20151201

The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer. ...[more]

Similar Datasets

Unknown MEK and the inhibitors: from bench to bedside.
| S-EPMC3626705 | biostudies-literature
Unknown T-cell inhibitors: a bench-to-bedside review.
| S-EPMC3485635 | biostudies-literature
Unknown RTK Inhibitors in Melanoma: From Bench to Bedside.
| S-EPMC8038208 | biostudies-literature
Unknown CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
| S-EPMC5610030 | biostudies-literature
Unknown B-Raf and the inhibitors: from bench to bedside.
| S-EPMC3646677 | biostudies-literature
Unknown New treatment option for ovarian cancer: PARP inhibitors.
| S-EPMC4880823 | biostudies-literature
Transcriptomics Molecular Diagnostics in Sepsis: from Bedside to Bench
2006-08-29 | GSE5663 | GEO
Unknown Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
| S-EPMC7812175 | biostudies-literature
Unknown Cancer photo-immunotherapy: from bench to bedside.
| S-EPMC7797676 | biostudies-literature
Unknown Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside.
| S-EPMC5675795 | biostudies-literature